Open access peer-reviewed Edited Volume

Pneumococcal Vaccines - Recent Advances, New Perspectives and Applications

Shailendra K. Saxena

King George's Medical University, India

A pioneering researcher in medical microbiology, host-pathogen interaction including the development of predictive, preventive, therapeutic strategies for them, author of the first book on COVID-19, and fellow of various learned societies of the world.

Covering

Immunity Preventive Antibiotics Immunotherapy Vaccines Pneumococcal Conjugate Vaccines Pneumococcal Polysaccharide Vaccine Pneumonia Meningitis Bacteremia Risk Factors Transmission Symptoms and Complications Diagnosis and Treatment

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Pneumococcal disease is caused by bacteria called Streptococcus pneumoniae (pneumococcus). Pneumococcal infections can range from ear and sinus infections to pneumonia and bloodstream infections. There are vaccines to help prevent pneumococcal disease. Pneumococcal polysaccharide or conjugate vaccines are currently used, which are based on a limited set of polysaccharide antigens of the bacterial capsule. Although, polysaccharide vaccines require a constant change in composition in view of the fact that when vaccinating the population, bacterial serotypes that are not included in the vaccine begin to dominate and cause disease. Therefore, pneumococcal vaccines include more and more components; for example, pneumococcal conjugate vaccine (PCV) was first prepared as a 7-component preparation, then as a 13-component preparation, and now it is being prepared as a 20-component preparation. The inclusion of a large number of components and their modification with a protein adjuvant makes the vaccine difficult to control in terms of quality and safety and also expensive. In addition, the polysaccharide components of the vaccine do not provide a long immunological memory, which requires their modification with adjuvants or repetitive revaccination. Current trends in the development of vaccines against pneumococcal infection include the use of protein factors of bacterial pathogenicities, such as highly conservative lipoprotein or enzymes (nucleases, proteases, hemolysin, peptidase), which are preferable over polysaccharide vaccines due to the lower variability and higher immunogenicity. Vaccination is the most effective and scientifically based means of protection against infectious diseases, especially Pneumococcal disease.

This book examines several issues related to the development of vaccines for Pneumococcal disease. This book intends to provide the reader with a comprehensive overview of recent trends in Pneumococcal disease, as well as general concepts of immunobiology, pathology, metagenomics, antibacterial-pharmacology to current clinical recommendations in the management of Pneumococcal disease, highlighting the ongoing issues, recent advances, with future directions in diagnostic approaches and therapeutic strategies. The book focuses on various aspects and properties of Pneumococcal disease, whose deep understanding is very important for safeguarding the human race from more loss of resources and economies.

This book provides an overview of recent developments in the detection, monitoring, treatment, and control of Pneumococcal disease. This book will be a self-contained collection of scholarly papers targeting an audience of practicing medical and basic researchers, academics, Ph.D. students, and other scientists. The contents of the book will be written by multiple authors and edited by experts in the field.

Publishing process

Book initiated and editor appointed

Date completed: May 3rd 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: May 31st 2022

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: July 30th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 18th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 17th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Shailendra K. Saxena

Professor Dr. Shailendra K. Saxena is a vice dean and professor at King George's Medical University, Lucknow, India. His research interests involve understanding the molecular mechanisms of host defense during human viral infections and developing new predictive, preventive, and therapeutic strategies for them using Japanese encephalitis virus (JEV), HIV, and emerging viruses as a model via stem cell and cell culture technologies. His research work has been published in various high-impact factor journals (Science, PNAS, Nature Medicine) with a high number of citations. He has received many awards and honors in India and abroad including various Young Scientist Awards, BBSRC India Partnering Award, and Dr. JC Bose National Award of Department of Biotechnology, Min. of Science and Technology, Govt. of India. Dr. Saxena is a fellow of various international societies/academies including the Royal College of Pathologists, United Kingdom; Royal Society of Medicine, London; Royal Society of Biology, United Kingdom; Royal Society of Chemistry, London; and Academy of Translational Medicine Professionals, Austria. He was named a Global Leader in Science by The Scientist. He is also an international opinion leader/expert in vaccination for Japanese encephalitis by IPIC (UK).

View profile

Book chapters authored 12

Books edited 7

Introducing your Author Service Manager

Ms. Nera Butigan

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors, and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing or reviewing. I assist authors in preparing their full chapter submissions and track important deadlines to ensure they are met. I help to coordinate internal processes such as linguistic review and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire